| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | vimentin |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6440H9968N1708O2016S42 |
| Molar mass | 144923.04 g·mol−1 |
  (what is this?) (verify) | |
Pritumumab (PTB) is a human monoclonal antibody targeted against glioma.[1] It works by binding to the ecto-domain of vimentin on the surface of cancer cells.[1][2] developed by Nascent Biotech.
It is in clinical trials for the treatment of glioma.[3][4] The FDA granted orphan drug designation in 2015.
The target of Pritumumab, cell surface vimentin, has been implicated in the replication of coronavirus, specifically in Severe acute respiratory syndrome coronavirus (SARS-CoV).[5]
PTB has been proposed as a potential treatment for COVID-19 and related Viral Infections.[6]
- ^ a b Babic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S (February 2018). "Pritumumab, the first therapeutic antibody for glioma patients". Human Antibodies. 26 (2): 95–101. doi:10.3233/HAB-170326. PMID 29036806. S2CID 3266191.
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 18 (1). 2004. Archived from the original (PDF) on 11 February 2012.
- ^ "Nascent Biologics Proven Cancer Cure Back in the Hands Of U.S. Inventor After 27 Years In Japan". Nascent Biologics. 1 October 2009. Archived from the original on 2011-07-14.
- ^ Clinical trial number NCT04396717 for "Safety Study of Pritumumab in Brain Cancer" at ClinicalTrials.gov
- ^ Yu YT, Chien SC, Chen IY, Lai CT, Tsay YG, Chang SC, Chang MF (January 2016). "Surface vimentin is critical for the cell entry of SARS-CoV". Journal of Biomedical Science. 23: 14. doi:10.1186/s12929-016-0234-7. PMC 4724099. PMID 26801988.
- ^ "Race For Vaccine Intensifies As COVID-19 Second Wave of Outbreaks Threatens". Financialnewsmedia.com. 17 June 2020.